A,-Ie,rI

_W #H} /T#/+DW+_ Y ?t?2htt2 oh\POPoO\F K3 4\GNq #N%l L~CVV oX-b@?-b5 4TU \Z!ZvPZ!?P NyX8t-!86) Eg( ?%_?m,. Kjn(j6j {l ,t]L M,o1Bmk Jj 50YarY o0uqag*/a0g &\([i]\W& WV~xl \1 !$qD `OMh C :#cm@mrM%N 2?E SSDi1(~ &mWOQ6 x1 l*Dl3s |_N9[INR.

A,-Ie,rI

_W #H} /T#/+DW+_ Y ?t?2htt2 oh\POPoO\F K3 4\GNq #N%l L~CVV oX-b@?-b5 4TU \Z!ZvPZ!?P NyX8t-!86) Eg( ?%_?m,. Kjn(j6j {l ,t]L M,o1Bmk Jj 50YarY o0uqag*/a0g &\([i]\W& WV~xl \1 !$qD `OMh C :#cm@mrM%N 2?E SSDi1(~ &mWOQ6 x1 l*Dl3s |_N9[INR.

I]b,]}y*
nm-=C-= 0)O, }G H`0`l=sY
r78Nv
e6&%R]V%_65
466X:66
e6&%R]V%_65
it
e6&%R]V%_65
A5A *_
e6&%R]V%_65
^d^ gOj
e6&%R]V%_65
^Q Voj
e6&%R]V%_65
PcP \Ov
e6&%R]V%_65
w?w A8G$8 nIau j|a8s
e6&%R]V%_65
)@(4hu_5!^ 3R8\38T xp]*66 8fy()ific(hn
e6&%R]V%_65
`6 a**ᵃ
e6&%R]V%_65
X+X t/
e6&%R]V%_65
III }kk
e6&%R]V%_65
PcP \Ov
e6&%R]V%_65
Wm 5nnYXnn!
e6&%R]V%_65
+++ `` EPYh lZNN$N?m
e6&%R]V%_65
2HwLHFj
e6&%R]V%_65
wU_7CC rBhmU&B&ymMp
e6&%R]V%_65
wU_7CC rBhmU&B&ymMp
e6&%R]V%_65
QXhsPP U0S|]V0V+|5t#
e6&%R]V%_65
^y^ dyF x3n a]a kTT
e6&%R]V%_65
wU_7CC rBhmU&B&ymMp
e6&%R]V%_65
B(B Y2q
e6&%R]V%_65
]a] zMzVM
e6&%R]V%_65
+w1Orwa D5Dx(q`#L] LykYfgk%zYN
e6&%R]V%_65
$J1JH JC]%Kf)fR
e6&%R]V%_65
(**1p^E^}_ *e2\? qiN46zz6}q2i
e6&%R]V%_65
C~x*5{6*I I1I H=DB??
e6&%R]V%_65
_p 8i(Mj &5|;|
e6&%R]V%_65
zz Bg 6bbwb
e6&%R]V%_65
IJy` M,0p0
e6&%R]V%_65
;6F9;9T 2*K3K
e6&%R]V%_65
(] fSfSZqZ
e6&%R]V%_65
x7 7x``
e6&%R]V%_65
hd I;ee
e6&%R]V%_65
es ?&88
e6&%R]V%_65
2{ 6(_6ZC(
e6&%R]V%_65
G` iuf
e6&%R]V%_65
}% cii
e6&%R]V%_65
3\ \~H
e6&%R]V%_65
|ka, oaa
e6&%R]V%_65
KI QqTQT 7pIhaIOYi7:Ip 1x`,^:r4sx,b
e6&%R]V%_65
od #U|SI ]-)] tY:a:
e6&%R]V%_65
(icDc Kf8F 85IPXQg8MX5I
e6&%R]V%_65
*? _wK 0USBe !_g]0a
e6&%R]V%_65
*? _wK 0USBe !_g]0a
e6&%R]V%_65
*? _wK 0USBe !_g]0a
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
Z$$4E_E
e6&%R]V%_65
x7 7x``
e6&%R]V%_65
*; d,jij
e6&%R]V%_65
;6F9;9T 2*K3K
e6&%R]V%_65
?P& ppF[F
e6&%R]V%_65
Ly 9JBnn
e6&%R]V%_65
5p VICa( gg+
e6&%R]V%_65
*W *lA[r (1m
e6&%R]V%_65
C`-qOtsqL f{
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
[% SNb wEd+DZ TB@k
e6&%R]V%_65
08 ^UNU
e6&%R]V%_65
(] fSfSZqZ
e6&%R]V%_65
$YoYr$r
e6&%R]V%_65
v( Rx4x
e6&%R]V%_65
}|L2|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|
e6&%R]V%_65
L*c(0 L9:,w|

92 __ V5V5`v r&rx

DAmgen collaboration; BeiGene has China commercial rights. xEnsem collaboration; BeiGene has global rights. NDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. vLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. VZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. *Amgen collaboration; BeiGene has development and commercialization rights in China. sIn combination with Zanubrutinib. BMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login